EGFR and neoplasm: Besides EGFR expression levels, other factors, such as EGFR mutations, tumor microenvironment, tumor vasculature density and permeability, tumor interstitial pressure, pharmacokinetics, and tumor penetration ability of compounds, could influence anti-EGFR treatments [8, 9, 23, 24].